by Jason Heaviland | Jun 24, 2026
How Exposomics Is Measured: Sample Types, Sensitivity, and Workflows How are exposomics measurements performed, what sample types can be analyzed, and how sensitive are modern exposomics assays? In this episode of ChatGJP, Panome Bio VP of Operations Adam Richardson...
by Jason Heaviland | Jun 12, 2026
ChatGJP: Discovery vs Targeted Exposomics Explained Should you use discovery exposomics or targeted exposomics? In this episode of ChatGJP, Panome Bio CEO Ed Weinstein explains the strengths of each approach and how they work together to provide a comprehensive...
by Jason Heaviland | Jun 2, 2026
ChatGJP: Exposomics, PFAS, and Clinical Trial Implications In this episode of ChatGJP, Panome Bio President and Co-Founder Tom Cohen explores the growing field of exposomics and its role in understanding how environmental exposures influence human health and disease....
by Jason Heaviland | Apr 30, 2026
Advancing the frontier of translational proteomic insights: Focus on large scale mass spectrometry A fireside conversation for biopharma, investors, and academics about maximizing translational insights from proteomic data by capitalizing on the emergence of...
by Jason Heaviland | Mar 2, 2026
Chemical Exposure Profiling of Alzheimer’s Patients This webinar presents a comprehensive overview of chemical exposure profiling in Alzheimer’s patients using Panome Bio’s Targeted Exposomics™ and Discovery Exposomics™ platforms. Learn how quantitative exposure...
